

Biosignal Limited

Suite 145, Level 1
National Innovation Centre
Australian Technology Park
EVELEIGH NSW 1430

Telephone +61 2 9209 4126
Facsimile +61 2 9209 4306

ACN 071 781 363
ABN 45 071 781 363

ASX Announcement

Biosignal Appoints New Directors

7 May 2009, Sydney: Biosignal Limited (ASX: BOS) wishes to advise that pursuant to the terms of the placement mandate with Empire Investments Ltd., it has appointed three new Directors to the Board: Mr Manraj Khosa, an experienced corporate attorney; Mr Timothy Morrison, a seasoned commercialisation executive; and Professor Michael Henderson, an executive with significant experience in business development in health and other fields both in Australia and the Asian region.

Enquiries: Professor Peter Steinberg
(02) 9209-4106
0422 048 730
p.steinberg@biosignal.com.au

About Biosignal

Biosignal is commercialising a distinctive anti-bacterial technology. This technology is effective across applications ranging from industrial to medical products. The first target applications are industrial products such as inhibitors of microbial corrosion for the oil and gas industry.

Biosignal's anti-biofilm technology is based on a discovery that the eastern Australian seaweed *Delisea pulchra* produces natural furanones that disable bacteria's ability to colonise. One fundamental problem with existing anti-bacterials, including antibiotics, is bacterial resistance. Bacteria rapidly produce resistant strains when faced with strong selective pressure by biocides. Furanones lull bacteria to inaction and appear to avoid the problem of bacterial resistance.